一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Pharmacological research >>article
Pharmacological research

Pharmacological research

IF: 9.1
Download PDF

Advancing precision therapy for colorectal cancer: Developing clinical indications for multi-target kinase inhibitor BPR1J481 using patient-derived xenograft models

Published:1 January 2025 DOI: PMID: 39709137
Ya-Chu Tang , Jing-Jim Ou , Shu-Ching Hsu , Chih-Hsiang Huang , Li-Mei Lin , Hsin-Huei Chang , Yi-Hsin Wang , Zih-Ting Huang , Manwu Sun , Ko-Jiunn Liu , Yi-Mei Hung , Chi-Yun Lai , Chuan Shih , Chiung-Tong Chen , Jang-Yang Chang , Hsing-Pang Hsieh , Weir-Torn Jiaang , Ching-Chuan Kuo

Abstract

The large and rapid increase in the incidence and mortality of colorectal cancer (CRC) demonstrates the urgent need for new drugs with higher efficacy to treat CRC. However, the lack of applicable and reliable preclinical models significantly hinders the progress of drug development. Patient-derived xenograft (PDX) models are currently considered reliable in vivo preclinical models for predicting drug efficacy in cancer patients. This study successfully uses the CRC PDX model to develop clinical indications for the new multi-target kinase inhibitor BPR1J481 and demonstrated the anti-cancer mechanism and competitive advantages of this drug candidate. The results demonstrate that BPR1J481 exhibits significant anticancer efficacy by inducing apoptosis in CRC PDX tumor tissues and corresponding PDX-derived CRC cells. Through kinase competitive binding and kinase activity assays, we discover that BPR1J481 effectively inhibits SRC kinase activity by directly binding to its active site. The reduction in SRC phosphorylation observed in CRC PDX tumor tissues and derived cells upon treatment with BPR1J481 further validates its inhibitory potential. Furthermore, the decrease in viable cells after SRC knockout and the poorer prognosis observed in patients with higher SRC expression, emphasizes the critical significance and clinical relevance of SRC in CRC. Additionally, BPR1J481 exhibits robust anti-angiogenic effects by suppressing VEGF- and PDGF-induced endothelial cell proliferation, migration, and capillary-like tube formation through inhibition of VEGFR2 and PDGFRβ phosphorylation. Remarkably, BPR1J481 appears to demonstrate greater efficacy against CRC compared to regorafenib. These findings highlight the therapeutic potential of BPR1J481 for patients with CRC.

Similar articles

IF:4.6

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.

Clinical Pharmacokinetics Neeraj Gupta, Michael J Hanley,etc Published: 1 August 2023
IF:1.8

Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy.

Anti-Cancer Drugs Tim Holzinger,?Julia Frei,etc Published: 1 November 2024
IF:3.6

Ginkgo biloba extract: Mechanisms and clinical indications

Archives of physical medicine and rehabilitation Bruce J. Diamond PhD, Samuel C. Shiflett PhD,etc Published: 1 May 2000
永济市| 汉中市| 桂东县| 邢台县| 海阳市| 和平区| 富民县| 中山市| 岑巩县| 涞源县| 礼泉县| 广东省| 永宁县| 成武县| 福清市| 大丰市| 聂拉木县| 德阳市| 怀来县| 闽侯县| 高淳县| 神池县| 时尚| 江阴市| 北碚区| 西和县| 宁南县| 延川县| 台中县| 中宁县| 红河县| 稷山县| 五大连池市| 滦平县| 阳朔县| 丰顺县| 茶陵县| 富源县| 崇仁县| 子洲县| 盐池县|